Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 21Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma, Follicular 12Lymphoma 11Lymphoma, B-Cell, Marginal Zone 7Recurrence 6Burkitt Lymphoma 6Neoplasms 5Lymphoma, B-Cell 5Leukemia, Hairy Cell 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Waldenstrom Macroglobulinemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Leukemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Macular dystrophy, corneal type 1 1Lymphatic Diseases 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 5fludarabine 4Mycophenolic Acid 4fludarabine phosphate 3blinatumomab 3Whole-Body Irradiation 3Tacrolimus 3Busulfan 3asciminib 2Rituximab 2Inotuzumab Ozogamicin 2Cytarabine 2Cyclosporine 2venetoclax 1tocilizumab 1ruxolitinib 1ricolinostat 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1nilotinib 1idelalisib 1ibrutinib 1ceralasertib 1Vincristine 1Thiotepa 1Surveys and Questionnaires 1Prednisone 1Midazolam 1Methotrexate 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × Rituximab × 30 days × Clear all
NCT01446133 2026-05-22

Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL)

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05645718 2026-05-19

Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

M.D. Anderson Cancer Center

Phase 2 Recruiting
27 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡